Background And Study Aims: Recent progress in chemotherapy has prolonged the survival of patients with malignant biliary strictures, leading to increased rates of stent occlusion. Occlusion of covered metallic stents now occurs in about half of all patients with malignant biliary strictures. The removal of metallic stents followed by placement of a second stent has been attempted, but outcomes remain controversial. The aim of the current study was to evaluate the effectiveness and safety of the primary placement and secondary placement (re-intervention) of covered metallic stents and to assess the feasibility and safety of stent removal.
Patients And Methods: The study included 186 patients with unresectable malignant biliary strictures who underwent primary stent placement between October 2001 and March 2010. Covered biliary self-expandable metal stents (SEMSs) were removed in 39 of these patients, and 36 underwent re-intervention. The patency times, occlusion rates of the first stent and re-intervention, success rates of stent removal, and complications were investigated.
Results: Covered SEMSs were placed in 186 patients. The median patency time of the first stent was 352 days. Stent occlusion occurred in 48.9 % of the patients and was mainly caused by debris or food residue (37 %), dislocation (19 %), and migration with hyperplasia (19 %). Stent removal was attempted in 50 patients and was successful without complication in 39 (78 %). Most of the patients in whom stent removal was unsuccessful had migration with hyperplasia. The median patency time of the second stent was 263 days. The stent patency time did not significantly differ between the first and the second stent.
Conclusions: Covered SEMSs could be safely removed at the time of stent occlusion. Patency rates were similar for initial stent placement and re-intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/s-0030-1256769 | DOI Listing |
Front Med (Lausanne)
January 2025
University of Illinois College of Medicine, Chicago, IL, United States.
Serum levels of the tumor marker CA 19-9 are widely utilized in the diagnosis and monitoring pancreatic and biliary malignancies. However, serum levels of CA 19-9 have also been reportedly elevated in non-malignant conditions. Here, we present the rare case of a 65-year-old woman with a history of gallbladder malignancy who was found to have a new hepatic lesion on surveillance CT with an associated elevation in CA 19-9 to 5,866 U/mL.
View Article and Find Full Text PDFCancer
February 2025
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Background: This study aims to explore the genetic characteristics of biliary tract cancer (BTC), with a particular focus on the impact of DNA damage response and repair (DDR) genes on clinical outcomes.
Methods: A total of 180 patients with BTC and next-generation sequencing data were retrospectively analyzed. Clinical outcomes were compared between DDR-positive and DDR-negative groups.
Clin Radiol
December 2024
University Hospital Southampton, Southampton General Hospital, Tremona Road, Southampton, Hampshire, SO16 6YD, UK. Electronic address:
Aim: Malignant biliary obstructive disease is commonly managed with percutaneous transhepatic biliary drainage (PTBD). Traditionally, outcomes are evaluated collectively despite substantial variability in the underlying aetiology and extent of disease. The purpose of this study was to investigate whether variability in survival could be explained by different underlying patient and disease factors.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Department of Surgery, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; University of California, Center for Global Surgery, Sacramento, CA, USA.
Introduction And Importance: Gallbladder cancer (GBC) is a rare but aggressive malignancy, accounting for most biliary tract cancers. It typically presents at an advanced stage, leading to a poor prognosis, with a mean survival of six months and a five-year survival rate of 17.6 %.
View Article and Find Full Text PDFRev Esp Enferm Dig
January 2025
Biliopancreatic Endoscopic Surgery, The Second Hospital of Hebei Medical University, .
Biliary signet-ring cell carcinoma is a rare malignant tumor of the biliary tract. signet-ring cell carcinoma often occurs in the gastrointestinal tract. In this case, we can intuitively see the location, shape and scope of the tumor through endoscopic ultrasonography (EUS) combined with a peroral direct choledochoscope.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!